Study of CJC-1134-PC, a novel GLP-1 receptor agonist in patients with type 2 diabetes mellitus

Trial Profile

Study of CJC-1134-PC, a novel GLP-1 receptor agonist in patients with type 2 diabetes mellitus

Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Mar 2015

At a glance

  • Drugs Albenatide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Mar 2015 Study title is not official
    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top